



IMPORTANT – This notice is important and requires your immediate attention. If you have any questions about the content of this notice, you should seek independent professional advice. The directors of the Company accept full responsibility for the accuracy of the information contained in this notice and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts, the omission of which would make any statement misleading.

14 December 2020

Dear Hong Kong Shareholder,

We are writing to inform you of the following changes to be made to the Hong Kong Offering Document (comprising the Prospectus, Hong Kong Covering Document, and Product Key Facts Statements of the Authorised Sub-Funds). All capitalised terms used in this notice and not defined herein shall have the meanings ascribed to them in the existing Hong Kong Offering Document.

A. Change of Chinese fund names

As part of the Chinese rebranding exercise, the Chinese name of T. Rowe Price will change from “普信” to “普徠仕”. Accordingly, with effect from 31 January 2021, the Chinese name of T. Rowe Price Funds SICAV will change from “普信 SICAV” to “普徠仕(盧森堡)系列”. Besides, the Chinese names of the following Authorised Sub-Funds will change as follows:

Authorised Sub-Funds	Current Chinese fund name	New Chinese fund name
Diversified Income Bond Fund	多元入息債券基金	多元收益債券基金
Emerging Local Markets Bond Fund	新興本地市場債券基金	新興市場本地債券基金
Euro Corporate Bond Fund	歐元公司債券基金	歐元企業債券基金
Global High Income Bond Fund	環球高收入債券基金	環球高息債券基金

English names of T. Rowe Price Funds SICAV and the Authorised Sub-Funds will remain unchanged.

B. Change of Chinese company name of Hong Kong Representative and a Sub-Investment Manager

The Chinese company name of T. Rowe Price Hong Kong Limited, the Hong Kong Representative and a Sub-Investment Manager of T. Rowe Price Funds SICAV will change from “普信香港有限公司” to “普徠仕香港有限公司” between now and 31 January 2021.

In spite of the above changes, there is no material change to the key features of the Authorised Sub-Funds (including the investment objectives, strategies, overall risk profiles, level of fees and the way they are being managed). It is not expected that the rights and interests of the Shareholders of the Authorised Sub-Funds will be materially prejudiced as a result of the changes set out in this notice. For your information, we set out below the list of Authorised Sub-Funds of the Company.

- Asia Credit Bond Fund
- Asian ex-Japan Equity Fund
- Asian Opportunities Equity Fund
- Diversified Income Bond Fund
- Emerging Local Markets Bond Fund
- Emerging Markets Bond Fund
- Emerging Markets Discovery Equity Fund
- Emerging Markets Equity Fund
- Euro Corporate Bond Fund
- European Equity Fund
- European High Yield Bond Fund
- Frontier Markets Equity Fund
- Global Aggregate Bond Fund
- Global Equity Dividend Fund
- Global Focused Growth Equity Fund
- Global High Income Bond Fund
- Global Natural Resources Equity Fund
- Global Technology Equity Fund
- Japanese Equity Fund
- Multi-Asset Global Income Fund
- Science and Technology Equity Fund
- US Blue Chip Equity Fund
- US High Yield Bond Fund
- US Large Cap Growth Equity Fund
- US Smaller Companies Equity Fund

The Hong Kong Offering Document will be updated to reflect the above changes in due course. The Hong Kong Offering Document may be inspected free of charge at the office of the Hong Kong Representative during normal business hours. Should you have any queries in relation to this matter, please do not hesitate to contact the Hong Kong Representative at 6/F, Chater House, 8 Connaught Road Central, Hong Kong (+852 2536 7800).

Yours faithfully,

Ian Hoddy

Director